Botulinum Toxin Injection for the Management of BPH
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is a double-blind randomized phase II trial to determine whether two different doses of
BoNT/A injection into the prostate gland demonstrate sufficient improvement in the management
of lower urinary symptoms due to BPH to warrant more extensive research. Subjects will
receive either a 100U or 300U dose. Participation will last 1 year.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator:
George Washington University
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA